DiaMedica Therapeutics Inc [DMAC] stock prices are up 0.20% to $5.06 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The DMAC shares have gain 11.45% over the last week, with a monthly amount glided 32.81%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
DiaMedica Therapeutics Inc [NASDAQ: DMAC] stock has seen the most recent analyst activity on October 07, 2024, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $7. On June 22, 2023, upgrade upgraded it’s rating to Outperform but maintained its price target of $7 on the stock. Oppenheimer started tracking the stock assigning a Outperform rating and suggested a price target of $27 on April 09, 2021. ROTH Capital initiated its recommendation with a Buy and recommended $38 as its price target on February 17, 2021. Guggenheim started tracking with a Buy rating for this stock on October 30, 2020, and assigned it a price target of $16. In a note dated July 08, 2020, Maxim Group initiated an Buy rating and provided a target price of $14 on this stock.
The stock price of DiaMedica Therapeutics Inc [DMAC] has been fluctuating between $3.19 and $6.82 over the past year. Currently, Wall Street analysts expect the stock to reach $8.33 within the next 12 months. DiaMedica Therapeutics Inc [NASDAQ: DMAC] shares were valued at $5.06 at the most recent close of the market. An investor can expect a potential return of 64.62% based on the average DMAC price forecast.
Analyzing the DMAC fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.7, Equity is -0.61 and Total Capital is -0.85. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.84 points at the first support level, and at 4.62 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.44, and for the 2nd resistance point, it is at 5.82.
Ratios To Look Out For
It’s worth pointing out that DiaMedica Therapeutics Inc [NASDAQ:DMAC]’s Current Ratio is 8.02. As well, the Quick Ratio is 8.02, while the Cash Ratio is 0.55.
Transactions by insiders
Recent insider trading involved STAHLBERG JAN, 10% Owner, that happened on Jul 23 ’25 when 1.54 million shares were purchased. 10% Owner, Von Koch Thomas completed a deal on Jul 23 ’25 to buy 2.86 million shares. Meanwhile, 10% Owner JACINTO RICHARD II bought 0.4 million shares on Jul 23 ’25.
